Have a feature idea you'd love to see implemented?
Let us know!
MTNB Matinas BioPharma Holdings Inc
Price (delayed)
$3.21
Market cap
$16.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.5
Enterprise value
$15.13M
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has
Highlights
Matinas BioPharma Holdings's debt has decreased by 16% YoY and by 4.6% QoQ
The EPS has grown by 8% from the previous quarter
The company's quick ratio rose by 47% QoQ but it fell by 31% YoY
The company's equity fell by 31% YoY but it rose by 31% QoQ
The gross profit has dropped by 100% year-on-year
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
Key stats
What are the main financial stats of MTNB
Market
Valuations
Earnings
Shares outstanding
5.02M
Market cap
$16.1M
Enterprise value
$15.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$22.91M
EBITDA
-$21.95M
Free cash flow
-$17.89M
Per share
Balance sheet
Liquidity
EPS
-$5.5
Free cash flow per share
-$3.59
Book value per share
$3.81
Revenue per share
$0
TBVPS
$4.62
Total assets
$24.37M
Total liabilities
$5.26M
Debt
$3.24M
Equity
$19.1M
Working capital
$12.89M
Debt to equity
0.17
Current ratio
6.39
Quick ratio
6
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-92.7%
Return on equity
-120.5%
Return on invested capital
-113.6%
Return on capital employed
-104.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MTNB stock price
How has the Matinas BioPharma Holdings stock price performed over time
Intraday
-4.46%
1 week
-21.32%
1 month
-10.34%
1 year
-67.93%
YTD
-70.31%
QTD
-9.32%
Financial performance
How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.76M
Net income
-$22.91M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
The company's net income fell by 11% YoY
The operating income has contracted by 4.7% YoY
Growth
What is Matinas BioPharma Holdings's growth rate over time
Valuation
What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
0.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 8% from the previous quarter
The stock's price to book (P/B) is 76% less than its 5-year quarterly average of 3.5 and 65% less than its last 4 quarters average of 2.4
The company's equity fell by 31% YoY but it rose by 31% QoQ
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
Efficiency
How efficient is Matinas BioPharma Holdings business performance
The ROE has dropped by 98% year-on-year and by 10% since the previous quarter
The return on assets has dropped by 85% year-on-year and by 8% since the previous quarter
Matinas BioPharma Holdings's ROIC has plunged by 76% YoY and by 4.1% from the previous quarter
Dividends
What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MTNB.
Financial health
How did Matinas BioPharma Holdings financials performed over time
The company's quick ratio rose by 47% QoQ but it fell by 31% YoY
MTNB's current ratio is down by 31% year-on-year but it is up by 24% since the previous quarter
Matinas BioPharma Holdings's debt is 83% lower than its equity
The company's equity fell by 31% YoY but it rose by 31% QoQ
The company's debt to equity fell by 26% QoQ but it rose by 21% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.